| Bioactivity | Becampanel (AMP397) is the first competitive AMPA antagonist and an antiepileptic agent. | ||||||||||||
| Invitro | Becampanel is negative in a mouse lymphoma tk assay, which includes a 24 h treatment without S9. A weak micronucleus induction in vitro is found at the highest concentrations tested in V79 cells with S9[1]. | ||||||||||||
| In Vivo | Becampanel is negative in the following in vivo studies, which includes the maximum tolerated doses of 320 mg/kg in mice and 2000 mg/kg in rats. Becampanel has no genotoxic potential in vivo[1]. | ||||||||||||
| Name | Becampanel | ||||||||||||
| CAS | 188696-80-2 | ||||||||||||
| Formula | C10H11N4O7P | ||||||||||||
| Molar Mass | 330.19 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Suter W, et al. Genotoxicity assessment of the antiepileptic drug AMP397, an Ames-positive aromatic nitro compound. Mutat Res. 2002 Jul 25;518(2):181-94. |